Author

Linda McNamara

Observed names: L McNamara, L. McNamara, McNamara, Linda

Observed institutions: Kyowa Kirin International (United Kingdom), Roche (United Kingdom)

ORCID: 0009-0000-4303-3791

Observed ORCID: 0009-0000-4303-3791

OpenAlex ID: A5016636620

Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care

2023 · Neil Hawkins, Noemi Muszbek, et al. · Journal of Comparative Effectiveness Research · 6

Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome

2022 · Neil Hawkins, Noemi Muszbek, et al. · Journal of Comparative Effectiveness Research · 5

Health state utilities associated with caring for an individual with cutaneous T-cell lymphoma (CTCL)

2020 · Kate Williams, Adam Gibson, et al. · Journal of Medical Economics · 5

Cost–utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma

2023 · Noemi Muszbek, Edit Remak, et al. · Journal of Comparative Effectiveness Research · 1

P12 Are Gains in Health Utility Associated with Gains in Work Productivity and Role Functioning in Chronic Diseases? A Systematic Literature Review

2022 · D Aggio, A Williams, et al. · Value in Health · 1

OP437 Use Of Real-World Evidence In Survival Analysis Adjusting For Treatment Crossover In Cutaneous T-Cell Lymphoma

2021 · Neil Hawkins, Rachel Evans, et al. · International Journal of Technology Assessment in Health Care · 1

Testing The Utility Of The Nhs's Systemic Anti-Cancer Therapy Data Set For Multi-Indication Pricing

2014 · L. McNamara, S. McNamara · Value in Health · 1

POSC133 Use of Expert Elicitation to Extrapolate Observed Intermediate Clinical Trial Outcomes to Clinically Meaningful Long-Term Outcomes for Use in Health Technology Assessments: A Case Study in a Rare, Lifelong Disease

2022 · R Evans, A Williams, et al. · Value in Health

PCN333 Analysis of Hospital Episode Statistics Data to Demonstrate the Secondary Care Treatment Pathway and Outcomes of Patients with Cutaneous T-Cell Lymphoma in England

2020 · N. Muszbek, F. Glen, et al. · Value in Health

PCN344 End of Life Secondary Care Resource Use and Costs in Mycosis Fungoides and Sézary Syndrome: An Analysis of Hospital Episode Statistics

2020 · N. Muszbek, F. Glen, et al. · Value in Health

88 A network's experience of using data to benchmark and improve 1-year survival rates in lung cancer

2012 · S. Lok, B. Gill, et al. · Lung Cancer

Works count: 13

Citation count: 20

H-index: 3

I10-index: